Meridian Bioscience price target raised to $24 from $22 at RW Baird Baird raised its price target on Meridian Bioscience following meeting with management. The firm believes investors sentiment is low but feels comfortable with guidance and management strategy for growth. Shares are Outperform rated.
Meridican says illumigene receives FDA clearance Meridian Bioscience announced that it has received FDA clearance for two new molecular assays for the detection of Herpes Simplex Virus Type 1 and Type 2, to be run on its illumigene molecular platform. The illumigene HSV 1&2 assays, launched earlier this year in Europe, are now available immediately in the U.S.